Therapeutic Monoclonal Antibodies - From Lot Release to Stability Testing

Harleen Kaur (Biologics Division, Aurobindo Pharma Ltd., Hyderabad, India)

$264.95

Paperback

Forthcoming
Pre-Order now

QTY:

English

Academic Press Inc
15 June 2024

Pharmacology; Biotechnology

Therapeutic Monoclonal Antibodies: From Lot Release to Stability Testing is a highly topical resource on a subject of interest for scientists and researchers working on monoclonal antibodies' characterization, release testing, stability testing and similarity assessments of monoclonal antibodies in the biopharmaceutical industry. Monoclonal antibodies (mAbs) are large, extremely complex and dynamic biomolecules, so it can be challenging to develop well-characterized therapeutic antibodies that meet regulatory expectations that are also in-line with commercialized standards for different drug markets.

Lot release testing and understanding the stability of the mAb over a period of time, and in different environmental conditions, is an indispensable aspect of mAb physicochemical characterization. This book covers the process, including extensive analysis that starts with quantifying the purity attribute to glycan profiling and identifying the mAb primary structure. The book has a primary purpose of focusing on both Lot release testing and stability testing of monoclonal antibodies (subjects not covered in any great detail in other books).

By: Harleen Kaur (Biologics Division Aurobindo Pharma Ltd. Hyderabad India)
Imprint: Academic Press Inc
Country of Publication: United Kingdom
Dimensions: Height: 229mm, Width: 152mm,
ISBN: 9780323906005
ISBN 10: 0323906001
Pages: 174
Publication Date: 15 June 2024
Audience: Professional and scholarly , Undergraduate
Format: Paperback
Publisher's Status: Forthcoming

1. General Characteristics 2. Purity analysis 3. N-Linked Oligosaccharide Profiling 4. Identity via Peptide Mapping and cIEF 5. Stability Testing

Harleen Kaur, PhD, is affiliated with Aurobindo Pharma Ltd., in the Biologics Division, based in Hyderabad, India. Dr Kaur is the lead editor of Monoclonal Antibodies: Physicochemical Analysis. Her research focuses on the analytical development and characterization of large molecules, particularly mAbs, and on bringing therapeutic products from early discovery to commercial launch. Previously she has worked for AstraZeneca both in the United States and India and has extensive experience in technology transfer and development of biologics in a highly regulated environment. She earned her undergraduate degree from Guru Gobind Singh Indraprastha University, Delhi, India, and PhD degree from the National University of Singapore, Singapore. She is the author of many peer-reviewed publications and book chapters in the area of antibody characterization and aptamers.